Wells Fargo’s Gyre Therapeutics GYRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$30.9K Sell
4,218
-12,079
-74% -$80.4K ﹤0.01% 5737
2026
Q2
$107K Buy
16,297
+12,007
+280% +$81.8K ﹤0.01% 5499
2026
Q1
$29.9K Sell
4,290
-8,629
-67% -$67K ﹤0.01% 5627
2025
Q4
$91.2K Buy
12,919
+7,361
+132% +$56.8K ﹤0.01% 5414
2025
Q3
$41.5K Sell
5,558
-1,457
-21% -$11.1K ﹤0.01% 5601
2025
Q2
$51.6K Buy
7,015
+2,907
+71% +$25.4K ﹤0.01% 5487
2025
Q1
$31.7K Buy
4,108
+92
+2% +$1.01K ﹤0.01% 5548
2024
Q4
$48.6K Buy
4,016
+913
+29% +$11.7K ﹤0.01% 5493
2024
Q3
$38.9K Buy
3,103
+116
+4% +$1.5K ﹤0.01% 5434
2024
Q2
$35.6K Buy
2,987
+2,891
+3,011% +$39.7K ﹤0.01% 5411
2024
Q1
$1.68K Buy
96
+2
+2% +$36 ﹤0.01% 6064
2023
Q4
$2.42K Buy
94
+81
+623% +$1.15K ﹤0.01% 6073
2023
Q3
$97 Hold
13
– – ﹤0.01% 6781
2023
Q2
$67 Buy
13
+1
+8% +$4 ﹤0.01% 6972
2023
Q1
$38 Hold
12
– – ﹤0.01% 7187
2022
Q4
$95 Hold
12
– – ﹤0.01% 6807
2022
Q3
$0 Sell
12
-1
-8% – ﹤0.01% 6916
2022
Q2
$0 Sell
13
-19
-59% – ﹤0.01% 7062
2022
Q1
$0 Hold
32
– – ﹤0.01% 7341
2021
Q4
$0 Hold
32
– – ﹤0.01% 7387
2021
Q3
$2K Sell
32
-1
-3% -$66 ﹤0.01% 6585
2021
Q2
$2K Sell
33
-3,716
-99% -$255K ﹤0.01% 6555
2021
Q1
$283K Sell
3,749
-650
-15% -$59.4K ﹤0.01% 4997
2020
Q4
$416K Buy
4,399
+2,937
+201% +$254K ﹤0.01% 4651
2020
Q3
$94K Buy
1,462
+702
+92% +$55K ﹤0.01% 5292
2020
Q2
$67K Buy
760
+599
+372% +$56.3K ﹤0.01% 5392
2020
Q1
$10K Sell
161
-202
-56% -$18.6K ﹤0.01% 5745
2019
Q4
$37K Sell
363
-234
-39% -$19.6K ﹤0.01% 5601
2019
Q3
$44K Sell
597
-1,770
-75% -$191K ﹤0.01% 5593
2019
Q2
$262K Sell
2,367
-472
-17% -$59K ﹤0.01% 4816
2019
Q1
$346K Sell
2,839
-28
-1% -$3.6K ﹤0.01% 4546
2018
Q4
$340K Sell
2,867
-493
-15% -$72.7K ﹤0.01% 4590
2018
Q3
$544K Buy
3,360
+1,078
+47% +$171K ﹤0.01% 4379
2018
Q2
$399K Buy
2,282
+1,686
+283% +$591K ﹤0.01% 4624
2018
Q1
$231K Buy
596
+356
+148% +$133K ﹤0.01% 4902
2017
Q4
$49K Buy
+240
New +$24.5K ﹤0.01% 5564
2017
Q3
– Hold
0
– – – 6365
2017
Q2
– Sell
-33
Closed -$2.37K – 6311
2017
Q1
$5K Buy
+33
New +$3.85K ﹤0.01% 6024
2016
Q4
– Hold
0
– – – 6332
2016
Q3
– Hold
0
– – – 6243
2016
Q2
– Hold
0
– – – 6191
2016
Q1
– Hold
0
– – – 6289
2015
Q4
– Hold
0
– – – 6303
2015
Q3
– Hold
0
– – – 6297
2015
Q2
– Hold
0
– – – 6412
2015
Q1
– Hold
0
– – – 6240
2014
Q4
– Hold
0
– – – 6288
2014
Q3
– Hold
0
– – – 6233
2014
Q2
– Hold
0
– – – 6181
2014
Q1
– Hold
0
– – – 5948
2013
Q4
– Hold
0
– – – 5810
2013
Q3
– Hold
0
– – – 5722
2013
Q2
– Hold
0
– – – 5627

Other funds holding GYRE

Wells Fargo's GYRE Position: Q3 2026 in Review

Wells Fargo reduced its Gyre Therapeutics (GYRE) stake by 74% in Q3 2026, selling an estimated $80.4K and leaving 4,218 shares worth $30.9K. The position accounts for ﹤0.01% of the portfolio, ranked #5737.

Wells Fargo first reported a position in GYRE in Q1 2017 and has held it in 37 quarters since. The position peaked at $544K in Q3 2018. 58 funds tracked by Wall St. Rank hold GYRE as of Q3 2026.

  • Wells Fargo held 4,218 shares of Gyre Therapeutics worth $30.9K as of Q3 2026.
  • Wells Fargo sold 12,079 Gyre Therapeutics shares in Q3 2026, an estimated $80.4K.
  • Gyre Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #5737 holding.
  • Wells Fargo first reported a position in Gyre Therapeutics in Q1 2017 and has held it in 37 quarters since.
  • Wells Fargo's Gyre Therapeutics position peaked at $544K in Q3 2018.
  • 58 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2026.

Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.